Explosive New NASDAQ $4 Biotech Receives $18 Analyst Target - 361% Upside (Symbol Inside)

BriaCell Therapeutics developer of Cancer treatments - Incredible upside New Focus Stock For Tuesday 2/6 BriaCell Therapeutics Corp. (NASDAQ: BCTX) $4/share Receives Staggering $18/share Analyst Price Target Representing an Incredible +361% Upside! [See $18.00 Price Target Proof Here]( Hi “FDR” Member, This is Michael Reece with “FinancialDrivenResearch” delivering you your new breakout alert for Tuesday trading session 2/6 BriaCell Therapeutics (NASDAQ: BCTX). I’ve been searching for a low priced explosive biotech situation with massive upside that has several Wall Street analysts that are bullish and has incredible upside potential. BriaCell Therapeutics (NASDAQ: BCTX) is priced just under $4/share and has a staggering $18/share analyst target price by H.C. Wainwright. [See here]( Bullish Catalyst - H.C. Wainwright Initiated Coverage BriaCell Therapeutics (NASDAQ: BCTX) with Buy rating and $18 Price Target ([Representing +361.53% in Upside Potential]( Initiating with Buy Rating and $18 PT According to H.C. Wainwright & Co. Analyst Emily Bodnar, BCTX Has +361.53% upside potential based on the analysts’ price target. Briacell Therapeutics (NASDAQ: BCTX) is a biotechnology company that focuses on developing innovative cancer immunotherapies. According to H.C. Wainwright & Co. Analyst Emily Bodnar and recent Blockbuster news BCTX showed promising signs reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients. BriaCell Therapeutics Corp. (NASDAQ: BCTX) lead targeted cell therapy Bria-IMT, when combined with the PD-1 inhibitor retifanlimab, achieved an [exceptional 71% intracranial objective response rate]( treating brain metastases in advanced breast cancer patients, according to H.C. Wainwright analyst Emily Bodnar in a December 28 research report. Of seven heavily pretreated patients with difficult-to-reach central nervous system lesions enrolled in the ongoing Phase 2 trial, five demonstrated either a partial or complete response. Bodnar believes this indicates Bria-IMT may effectively cross the blood-brain barrier, allowing unique antitumor activity against these metastatic tumors compared to existing standard-of-care therapies. CNS metastases occur in 10-15% of breast cancer patients overall, reaching as high as 25-50% in patients with aggressive HER2-positive or triple-negative disease subtypes. However, Bodnar highlights current targeted treatments like monoclonal antibodies or ADCs rarely exceed a 50% intracranial response rate based on historical data. "We believe an iORR of 71% is differentiated compared to SOC therapies available for breast cancer," Bodnar concludes. BriaCell Therapeutics is a clinical stage oncology-focused biotechnology company using cell-based immunotherapies to target breast and other cancers. The approach stimulates a cancer fighting immune response to destroy tumor cells. Lead candidate Bria-IMT™ is advancing in combination with other therapies including checkpoint inhibitors to combat breast cancer. Secondary candidate Bria-OTS™ addresses variation between patients with breast cancer and is based on a patient’s human leukocyte antigen (HLA) type. If successful, this product could address almost all third-line patients. In addition to Bria-IMT and Bria-OTS, the company offers a portfolio of other preclinical assets addressing prostate, non-small cell lung, melanoma and other cancers. In clinical work to date, BriaCell has shown a strong correlation between the efficacy of Bria-IMT and patients that have a close HLA match with the therapeutic cells. BriaCell is conducting a Phase I/IIa combination study and has released interim data demonstrating effective immune response and disease control in heavily pre-treated patients. BriaCell Therapeutics Highlights Present Incredible Shareholder Growth Novel targeted immunotherapy platform; Pivotal Phase 3 study underway - Awarded Fast Track designation by FDA - Pivotal Phase 3 study in advanced metastatic breast cancer (over 40K US deaths/year) - Safety & efficacy data similar or superior to other approved breast cancer drugs when at a comparable stage of development - Single agent and combination check point inhibitor (+ CPI) activity - Activity in CPI and antibody-drug conjugate (ADC) resistant patients - Activity in patients with CNS metastases - Bria-OTS™ “Off-The-Shelf Personalized” platform technology - Phase 1/2 IND open, commencing 1H2024 - Robust pipeline includes novel cellular immunotherapies for breast cancer, prostate cancer, lung cancer and melanoma - National Cancer Institute SBIR award BriaCell Therapeutics Pipeline - Bria-IMT™ CPI Combination -- Advanced Metastatic Breast Cancer (Fast Track) = Phase 3 - Bria-IMT™ CPI Combination -- Early Phase Breast Cancer = Investigator Initiated - Bia-OTS™ -- Breast Cancer = Phase 1/2 Initiation 1H2024 - Bria-Pros™ -- Prostate Cancer = IND Preparation 1H2024 - Bria-Lung™ -- Non-Small Cell Lung Cancer = IND Preparation 1H2024 - Bria-Mel™ -- Melanoma = IND Preparation 1H2024 BriaCell’s Therapeutics, Corp. Patented Immunotherapy Bria-IMT™, our lead drug candidate currently in Phase 3, is a patented, off-the-shelf, cell based, targeted immunotherapy that stimulates the patient’s immune system to induce targeted killing of cancer cells. Our data shows that Bria-IMT™, an off-the-shelf immunotherapy, expresses tumor antigens and granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate specific cancer fighting CD4+ and CD8+ T cells, and stimulates the immune system to enhance targeted killing of cancer cells. When combined with a check point inhibitor, which “releases the brakes”, Bria-IMT™, “steps on the gas” providing powerful anti-tumor activity. BriaCell recently announced initiation of a pivotal Phase 3 study in advanced metastatic breast cancer, which if successful could lead to full approval of Bria-IMT™ in combination with a check point inhibitor. BriaCell also announced completion of enrollment of advanced breast cancer patients in its randomized ongoing Phase 2 combination study of Bria-IMT™ with Incyte’s immune checkpoint inhibitor, retifanlimab. This study followed successful completion of a Phase 1 study showing a favorable safety and efficacy profile for the combination regimen. Data includes unprecedented activity in very advanced patients who have failed antibody-drug conjugate therapy and in patients with metastases to the central nervous system. Off-The-Shelf Personalized Immunotherapy Bria-OTS™ Our next generation personalized off-the-shelf immunotherapy, Bria-OTS™, Our next generation personalized off-the-shelf immunotherapy, Bria-OTS™, awarded numerous US and international patents and supported by clinical data, forms the basis of BriaCell’s “OTS” strategy. Introducing Bria-OTS™ - Bria-IMT™ is most effective in HLA – type matched patients - Bria-OTS™ is engineered to express 15 unique HLA types in 4 independent cell lines - Provides matched treatment to greater than 99% of patients with advanced breast cancer - Simple saliva test determines patient HLA type for delivery of personalized off-the-shelf Bria-OTS™ immunotherapy - Received a Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI) - Ongoing collaboration with the NCI - Similar cell lines in development for prostate cancer (Bria-Pros™), lung cancer (Bria-Lung™), and melanoma (Bria-Me™) including enhanced ability to activate resting (naïve) T cells What's Next For BriaCell Therapeutics, Corp? - Expand clinical sites and continue enrollment in pivotal Phase 3 registration study - Ongoing phase 2 patient data updates through 2024 - Bria-OTS™ (personalized off-the-shelf approach) platform technology clinical trial commencement - BriaCell immunotherapy appears to be most effective when patients match the Bria-IMT HLA-type - Bria-OTS™ developed to match the patient’s HLA-type. Simple saliva test to determine patients’ HLA-type - Designed to provide HLA matched therapy to >99% of patients with advanced breast cancer in 4 cell lines - Developed into a platform technology to provide personalized off-the-shelf immunotherapies for many cancers Summary Investor Conclusion & Highlights BriaCell Therapeutics Corp. clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies cancer care. Lead drug candidate Bria-IMT™ - Awarded Fast Track designation by FDA - Pivotal Phase 3 study in advanced metastatic breast cancer (over 40K US deaths/year) - Safety & efficacy data similar or superior to other approved breast cancer drugs when at a comparable stage of development - Single agent and combination check point inhibitor (+ CPI) activity - Activity in CPI and antibody-drug conjugate (ADC) resistant patients - Activity in patients with CNS metastases Bria-OTS™ “Off-The-Shelf Personalized” platform technology - Phase 1/2 IND open, commencing 1H2024 - Robust pipeline includes novel cellular immunotherapies for breast cancer, prostate cancer, lung cancer and melanoma. - National Cancer Institute SBIR award I am urging all of our “FDR” members to add BriaCell Therapeutics Corp. (NASDAQ: BCTX) to the top of your watch list right now, and be ready Tuesday morning at the opening bell! To Your Trading Success, Michael Reece Editor, Financial Driven Research © 2023 Financial Driven Research, All Rights Reserved. Financial Driven Research (“FDR” or “Company”) is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inves∙tment for any specific individual. FDR full disclosure is to be read and fully understood before using FDR website or joining FDR email or sms list. By viewing FDR website and/or reading FDR email or sms list you are agreeing to FDR full disclosure This publication may contain information regarding inves∙tment ideas and third-party ratings regarding specific securities. We hold n∙o inves∙tment licenses and are thus neither licensed nor qualified to provide inves∙tment adv∙ice. FDR nor its principals are not FINRA-registered broker-dealers or inves∙tment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from FDR to buy or sell any security. Always be extremely careful and consult a licensed inves∙tment professional before making any inves∙tment decision as inves∙ting in securities carries a high degree of risk; you may likely lose some or all of the inves∙tment. This communication is a sponsored advertisement. FDR and/or its subsidiaries and/or affiliates has been compensated $20,000 USD to disseminate this communication. Please note we do not hold positions in stocks we profile. We do not trade in any of our sponsored advertisements, or non-sponsored profiles. We do not accept stock as a form of payment for our sponsored advertisements. Please review the full disc∙laimer at [Disc∙laimer and Disclosure Policy]( for important information regarding this sponsored advertisement. © 2023 FDR. All rights reserved., 1014 W 36th St, Baltimore, MD 21211, United States You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](